Device Digest

Glenmark Pharmaceuticals’ GRC 54276 Receives FDA Approval for Clinical Trial to Treat Advanced Solid Tumors and Lymphomas

Glenmark Pharmaceuticals’ subsidiary, Glenmark Specialty SA, has received acceptance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for GRC 54276. The clinical trial will investigate GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas. GRC 54276 is an orally available small molecule hematopoietic progenitor […]